Delving into the Latest Updates on Filgotinib Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Filgotinib, Filgotinib hydrochloride, G-146034

+ [7]

Target

JAK1

Action

inhibitors

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)

Therapeutic Areas

Immune System DiseasesDigestive System DisordersSkin and Musculoskeletal Diseases+ [7]

Active Indication

Colitis, UlcerativeRheumatoid ArthritisUlcerative colitis, active moderate+ [7]

Inactive Indication

Ankylosing SpondylitisArthritis, PsoriaticCrohn Disease+ [6]

Originator Organization

Lakefront Biotherapeutics

Active Organization

Gilead Sciences, Inc.

Alfasigma SpAGilead Sciences Ireland UC

+ [2]

Inactive Organization

Lakefront Biotherapeutics

License Organization

Alfasigma SpA

Shanghai Abbott Pharmaceutical Co. Ltd.

Gilead Sciences, Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

European Union (24 Sep 2020),

Rheumatoid ArthritisUlcerative colitis, active moderateUlcerative colitis, active severe

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O7S

InChIKeyBFENHEAPFWQJFL-BTJKTKAUSA-N

CAS Registry1802998-75-9

Ulcerative colitis (UC) is a chronic bowel disease. It causes inflammation of the rectum and sometimes the colon. This disease can also affect other parts of the body. It can be very difficult to live with on a daily basis. People with UC may experience frequent diarrhea, rectal bleeding, urgency to defecate, and even incontinence. All of this can significantly reduce their quality of life.
The goal of treatment is twofold:
* To eliminate or reduce symptoms (this is clinical remission),
* To allow the bowel to heal.
When these two goals are achieved, the risk of relapse, hospitalization, surgery, or colorectal cancer decreases.
To monitor the progression of the disease, gastroenterologists use a test called fecal calprotectin: this is a protein measured in stool that helps detect intestinal inflammation.
When conventional treatments like corticosteroids or immunosuppressants are ineffective or poorly tolerated, the investigators use more targeted therapies.
For a long time, doctors have used drugs called anti-TNFs. They block a protein responsible for inflammation (TNF-alpha). These treatments are often injected under the skin, which is generally well-tolerated by patients.
A drug called infliximab, now available as a subcutaneous injection, could be used as a first-line treatment for ulcerative colitis because it appears to be more effective than other injectable anti-TNFs.
Another drug, vedolizumab, works differently from anti-TNFs and can also be used as a first-line treatment.
More recently, new classes of drugs have shown promise:
* JAK inhibitors (such as filgotinib),
* interleukin-12 and interleukin-23 inhibitors (such as ustekinumab).
These new treatments have advantages, such as the oral administration method for filgotinib and the fact that they can be used alone, without any other associated medication, which could simplify patients' lives and improve their quality of life.
Today, there are increasingly more different treatments for ulcerative colitis, and the investigators still don't know clearly what the best strategy is:
Is it better to start with one type of medication rather than another? Does the order in which the investigators try treatments lead to different results?
This is an important question for gastroenterologists, as their goal is to choose the most appropriate treatment for each patient from the outset.
The main objective of this research is to compare four strategies, corresponding to four treatment arms, starting with the use of infliximab, filgotinib, vedolizumab, or ustekinumab, to maintain remission in patients with ulcerative colitis.
The following four arms are therefore proposed:
* Based on efficacy: infliximab - filgotinib - ustekinumab - vedolizumab
* Based on safety: ustekinumab - vedolizumab - infliximab - filgotinib
* Based on current practice: vedolizumab - infliximab - filgotinib - ustekinumab
* Based on convenience and route of administration: filgotinib - ustekinumab - vedolizumab - infliximab
This study will also allow for a comparison of the efficacy, safety, participant acceptability, and quality of life of the four treatment regimens.
This study is intended for adult patients (aged 18 to 65), male or female, with moderate or severe ulcerative colitis (UC) for at least 3 months. Treatment for these patients must require biologic therapy, as determined by the investigator. Participants must be able to provide informed consent to participate in the research and must be covered by a national health insurance plan. Women of childbearing age must be using active contraception for at least the duration of the study (2 years).
Patients will be followed for two years. They will be seen at the initial visit, then every two months during the first year, and then every three months during the second year. At each visit, they will be required to undergo blood and stool tests and complete a questionnaire. Endoscopies will be scheduled for weeks 16, 52, and 104. Patient treatments can be optimized once, and based on the endoscopic score, patients may change treatments according to a predefined sequence.

Start Date01 Jun 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire de Clermont Ferrand

NCT07554495

/ RecruitingPhase 3

Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Polyarticular-course Juvenile Idiopathic Arthritis

This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.

Start Date21 May 2026

Sponsor / Collaborator

Alfasigma SpA

100 Clinical Results associated with Filgotinib Maleate

Login to view more data

100 Translational Medicine associated with Filgotinib Maleate

Login to view more data

100 Patents (Medical) associated with Filgotinib Maleate

Login to view more data

456

Literatures (Medical) associated with Filgotinib Maleate

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Filgotinib induces apoptosis in colorectal cancer cells by activating the p53 signaling pathway

Article

Author: Ye, Huiming ; Li, Zhen ; Zhao, Yanyang ; Zhou, Ying ; Li, Chenmeng

BACKGROUND:

Colorectal cancer remains a significant health challenge. Filgotinib is a selective JAK1 inhibitor approved for the treatment of inflammatory diseases. However, its anti-tumor effects and underlying mechanisms in colorectal cancer (CRC) remain unexplored.

METHODS AND RESULTS:

In this study, cell viability and proliferation were assessed by CCK‑8, crystal violet, and EdU assays. Mitochondrial membrane potential was evaluated using JC‑1 staining. Transcriptome sequencing (RNA‑seq) was performed on RKO cells treated with Filgotinib, followed by GO and KEGG pathway enrichment analyses. Protein expression was examined by Western blot. The effect of Filgotinib was further validated in three human CRC patient‑derived organoids (PDOs). Filgotinib at concentrations near the IC₅₀ (14 µM for HCT116, 10 µM for RKO, 14 µM for LoVo) reduced cell viability and proliferation, as shown by CCK‑8, crystal violet, and EdU assays. Western blot analysis confirmed reduced JAK1 and STAT3 protein expression after Filgotinib treatment compared with the control. Filgotinib induced mitochondrial‑dependent apoptosis, evidenced by increased green fluorescence in the JC‑1 assay. Transcriptomic profiling of RKO cells treated with 10 µM Filgotinib for 48 h identified 1,151 upregulated and 862 downregulated genes. GO analysis revealed enrichment in terms related to chromatin structure, nucleotide binding, and metabolic processes. KEGG analysis highlighted activation of the p53 signaling pathway and suppression of oncogenic pathways including VEGF and TNF signaling. At the protein level, Filgotinib treatment increased the expression of p21 (a key p53 pathway effector) and cleaved caspase-3 compared with the control group. Furthermore, treatment of human CRC-derived PDOs with Filgotinib (≥ 10 µM) for 48 h resulted in organoid disintegration.

CONCLUSIONS:

Our study demonstrates that Filgotinib exerts direct anti-tumor effects in CRC by triggering apoptosis, activating the p53 pathway, and inhibiting pro-survival VEGF and TNF pathways. These findings support its potential as a targeted therapeutic agent for CRC.

01 Oct 2026·JOINT BONE SPINE

Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study

Article

Author: Wada, Yumiko ; Nozaki, Yuji ; Yamamoto, Wataru ; Shirasugi, Iku ; Nakano, Naoki ; Yoshikawa, Ayaka ; Son, Yonsu ; Okada, Seiji ; Okita, Yasutaka ; Ebina, Kosuke ; Nakata, Ken ; Tsujimoto, Kohei ; Maeda, Yuichi ; Ashida, Chisato ; Noguchi, Takaaki ; Etani, Yuki ; Makino, Hidehiko ; Fujii, Takayuki ; Kumanogoh, Atsushi ; Watanabe, Ryu ; Hashimoto, Motomu

OBJECTIVE:

Herpes zoster (HZ) is a common adverse event associated with Janus kinase inhibitors (JAKi); however, direct comparisons using real-world data are lacking, which we aimed to clarify.

METHODS:

We retrospectively analyzed data from the multicenter ANSWER cohort, including 1,096 treatment courses from 765 patients with RA (84.1% female; mean age, 63.9 years; mean follow-up, 18.2 months) who initiated treatment with tofacitinib, baricitinib, peficitinib, upadacitinib, or filgotinib. Incidence rates (IRs) of HZ were calculated per 100 patient-years using exact Poisson method. Time-to-event and treatment retention analysis were performed using Kaplan-Meier methods, and hazard ratios (HRs) were estimated using Cox proportional hazards models adjusted for patient characteristics.

RESULTS:

During follow-up, HZ occurred in 88 treatment courses. The IRs per 100 person-years were 5.84 for tofacitinib, 6.21 for baricitinib, 3.79 for peficitinib, 7.38 for upadacitinib, and 1.73 for filgotinib. In the adjusted Cox model, filgotinib (reference) was associated with a significantly lower hazard of HZ compared with tofacitinib (HR, 7.68; 95% CI, 1.71-34.6; P=0.008), baricitinib (HR, 6.35; 95% CI, 1.48-27.1; P=0.013), and upadacitinib (HR, 4.75; 95% CI, 1.11-20.3; P=0.036), whereas no significant differences were observed in treatment retention. Patient-related variables, including age, sex, prior HZ, and vaccination history, were not significantly associated with HZ risk.

CONCLUSION:

Filgotinib showed a lower observed risk of HZ compared with tofacitinib, baricitinib, and upadacitinib. Given the limited number of events and observational design, further large-scale studies with longer follow-up are warranted to confirm these findings.

01 Aug 2026·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Comment on “Dose-dependent efficacy and safety of Filgotinib in moderate to severe Crohn’s disease: a grade-assessed systematic review and meta-analysis of randomized controlled trials”

Letter

Author: Laskar, Tanjima Tarique ; Borah, Sudarshana ; Arora, Monica

163

News (Medical) associated with Filgotinib Maleate

12 Aug 2026

·www.fiercepharma.com

Alfasigma gains arthritis drug, access to new markets with M&A play

In a deal announced this week, Alfasigma spent an undisclosed sum to continue its global expansion in immunology. The Italian drugmaker has laid plans to acquire Nordic Pharma, a niche pharmaceutical company specializing in rheumatology, women’s health and ophthalmology, from Sever Life Sciences. Under the deal—which is subject to closing conditions—Alfasigma will add key drugs like Nordimet, a methotrexate injection, to its rheumatology portfolio, which already includes Jyseleca, as well as Nordic Pharma’s women’s health, critical care and ophthalmology portfolios. Through Nordic Pharma, Alfasigma is set to tap into two new commercial markets, Japan and Canada, and will expand its operations across Europe, too. Nordic Pharma’s 2023 merger with Amring also gave the company a secure footprint in the US. Nordic's range of products includes a cystic fibrosis-specific nutritional supplement, treatments for medical termination of pregnancy and an FDA-cleared medical device for lacrimal occlusion. The transaction falls in line with Alfasigma’s playbook over the last several years. The company has repeatedly pursued an external growth trajectory, scooping up smaller pharmas—particularly in the rare disease, immunology and gastroenterology space—to expand its international presence. Alfasigma bought out Intercept Pharmaceuticals, makers of a rare liver disease treatment, in 2023, just weeks before acquiring its current rheumatology leader , Jyseleca, from Belgium-based Galapagos. Then, this spring, Alfasigma made a $300 million upfront bet on a licensing agreement with GSK for a chronic itch drug that immediately went on to win FDA approval. Jyseleca is an immunomodulatory drug, specifically a JAK-inhibitor, approved in Europe, the U.K. and Japan to treat inflammatory diseases like rheumatoid arthritis and ulcerative colitis. Alfasigma reported double-digit growth from the brand in 2025 and is currently pursuing approval from the European Medicines Agency for a new indication—axial spondyloarthritis, a chronic inflammatory arthritis of the spine. The drugmaker is seeking “the right opportunities to build our global specialty and rare disease business,” CEO Francesco Balestrieri said in a statement. While the transaction is still subject to regulatory approval, it’s expected to close by the end of 2026.

12 Aug 2026

·www.pharmaceutical-technology.com

Alfasigma signs agreement to acquire Nordic Group

The acquisition will bring Nordic Pharma’s rheumatoid arthritis business into Alfasigma’s portfolio. Credit: Stock-Asso / Shutterstock.com. Alfasigma has agreed to purchase Nordic Group, a move aimed at strengthening its speciality care business and expanding its reach in Europe, Canada, and Japan. The transaction is structured through a share purchase agreement with SEVER Life Sciences for 100% of Nordic Group and its subsidiaries. While specific financial terms have not been disclosed, the deal is subject to customary conditions, including relevant regulatory clearances. It will bring Nordic Pharma’s rheumatoid arthritis business, led by the Nordimet methotrexate franchise, into Alfasigma’s rheumatology portfolio. This portfolio currently includes Jyseleca, approved for second-line treatment in inflammatory and autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, and marketed by Alfasigma in the EU, EEA, and UK. In addition, the acquisition covers Nordic Pharma’s products in women’s health, critical care, and ophthalmology. Following the deal, Alfasigma will operate directly in 18 European countries, and extend its commercial activities to Canada and Japan. The addition of Nordic Pharma will see approximately 265 new employees join Alfasigma. Alfasigma CEO Francesco Balestrieri said: “Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology. “The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders.” Nordic Group CEO Charlotte Phelps said: “Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth. Both companies are patient-focused, rooted in science and entrepreneurial. We look forward to combining our experience to support patients.” Alfasigma is a privately owned pharmaceutical company headquartered in Italy, distributing products in more than 100 markets and employing around 4,000 people.

AcquisitionDrug Approval

11 Aug 2026

·www.biospace.com

Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet ® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed. BOLOGNA, Italy & MILAN, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet ® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca ® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise. The transaction is subject to customary closing conditions, including any required regulatory agency clearances. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The transaction supports Alfasigma’s M&A-led growth strategy as it actively expands its international specialty and rare business, with a focus on gastroenterology and immunology. It follows recent portfolio-building initiatives, including the acquisition of Jyseleca ® in inflammatory diseases and the licensing agreement with GSK for linerixibat for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients. Francesco Balestrieri, Chief Executive Officer, Alfasigma, said: “Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology. The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders.” Charlotte Phelps, Chief Executive Officer, Nordic Group B.V., commented: “Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth. Both companies are patient-focused, rooted in science and entrepreneurial. We look forward to combining our experience to support patients.” Forward looking statements This press release contains forward‑looking statements. Actual results may differ materially due to various risks and uncertainties, including regulatory outcomes and market conditions. About Alfasigma Alfasigma is a privately owned, medium-sized, global pharmaceutical company, headquartered in Italy with offices in Bologna and Milan. Its products are distributed in more than 100 markets worldwide. The company employs approximately 4,000 people. Alfasigma continues to expand its international presence and portfolio through acquisitions, partnerships, and licensing agreements. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic focus on gastroenterology, immunology, and vascular health. Visit . About Jyseleca ® (filgotinib) Approved for use as a second-line treatment in inflammatory and autoimmune diseases including rheumatoid arthritis and ulcerative colitis. Jyseleca is marketed by Alfasigma in EU and EEA countries and in the UK. About SEVER Life Sciences B.V. SEVER Life Sciences B.V. is an international life sciences group with activities spanning pharmaceutical development, manufacturing and specialty pharmaceuticals. Following completion, SEVER will continue to focus on the development of its remaining businesses, namely Sever Pharma Solutions AB, Farmaprim S.R.L., Esperante Development B.V. and Nordic Pharma Inc. About Nordic Group B.V. Nordic Group B.V. is an international specialty pharmaceutical company headquartered in Hoofddorp, The Netherlands, with a diversified portfolio of branded and niche pharmaceutical products marketed across Europe and selected international markets. Visit . Contacts For more information, please contact Irene Lawlor pressoffice@alfasigma.com

AcquisitionLicense out/inDrug ApprovalBiosimilar

100 Deals associated with Filgotinib Maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11106	Filgotinib Maleate	-	DB14845

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Colitis, Ulcerative	Japan	Gilead Sciences Ireland UC	28 Mar 2022
Rheumatoid Arthritis	European Union	Alfasigma SpA	24 Sep 2020
Rheumatoid Arthritis	Iceland	Alfasigma SpA	24 Sep 2020
Rheumatoid Arthritis	Liechtenstein	Alfasigma SpA	24 Sep 2020
Rheumatoid Arthritis	Norway	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active moderate	European Union	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active moderate	Iceland	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active moderate	Liechtenstein	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active moderate	Norway	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active severe	European Union	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active severe	Iceland	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active severe	Liechtenstein	Alfasigma SpA	24 Sep 2020
Ulcerative colitis, active severe	Norway	Alfasigma SpA	24 Sep 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Belgium	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Czechia	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	France	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Germany	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Hungary	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Italy	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Poland	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	Spain	Alfasigma SpA	21 May 2026
Polyarticular Juvenile Idiopathic Arthritis	Phase 3	United Kingdom	Alfasigma SpA	21 May 2026
Juvenile Idiopathic Arthritis	Phase 3	France	Alfasigma SpA	20 Apr 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03025308 (FINCH 4, CTgov)	Phase 3	Rheumatoid Arthritis	2,731	Filgotinib (Filgotinib 200 mg: With Prior Filgotinib Exposure)	qwkzftuotm = xwzaqojhdb dzalytsgas (htvifdfsfk, wqpmmgskdv - slmyfjtmoq) View more	-	27 Jul 2026
				Filgotinob (Filgotinob 200 mg: Without Prior Filgotinob Exposure)	qwkzftuotm = ybutynztfd dzalytsgas (htvifdfsfk, yvchkbdccf - ihhgdlcghr) View more
NCT05785611 (OLINGUITO, EULAR2026)	Phase 3	Axial Spondyloarthritis	495	Filgotinib 200 mg	cpczoirskd(xdnukgsbwu) = kiytwfttaq giuowoknob (aftimucojp ) View more	Positive	11 Jun 2026
				Placebo	cpczoirskd(xdnukgsbwu) = bjntnilnfc giuowoknob (aftimucojp ) View more
FINCH 4 (EULAR2026)	Phase 3	Rheumatoid Arthritis	3,452	Filgotinib 200 mg	hovuhurgji(ynkahuavyc) = xbrxemgvvv flyhlouxli (fwdcwegmoe ) View more	Positive	11 Jun 2026
				Filgotinib 100 mg	hovuhurgji(ynkahuavyc) = uzaabnegyn flyhlouxli (fwdcwegmoe ) View more
EULAR2026	Not Applicable	Rheumatoid Arthritis	3,691	Filgotinib 100 mg	zfyvwtiyze(dydiuusqrm) = htgvbigxfi eyvtutdrpq (icaanpcjbt, 0.4 - 0.7) View more	Positive	11 Jun 2026
				Filgotinib 200 mg	zfyvwtiyze(dydiuusqrm) = xlmbgnkeqk eyvtutdrpq (icaanpcjbt, 0.3 - 0.5) View more
EULAR2026	Phase 4	Rheumatoid Arthritis	1,306	Filgotinib 200 mg (AT-naïve patients)	fetkbdcdio(uoyylwimtg) = efqxvwrxfo ihclicjosk (intdltqmru ) View more	Positive	11 Jun 2026
				Filgotinib 200 mg (patients who had received 1 prior tumor necrosis factor (TNF) inhibitor)	fetkbdcdio(uoyylwimtg) = dywutfkupf ihclicjosk (intdltqmru ) View more
NCT05785611 (OLINGUITO, EULAR2026)	Phase 3	Axial Spondyloarthritis	-	Filgotinib 200 mg	ybiffurpjx(zbccbrdihk): P-Value = <0.001 View more	Positive	11 Jun 2026
				Placebo
DRKS00036136 (FIRST-RA, EULAR2026)	Not Applicable	Rheumatoid Arthritis	79	Filgotinib	wcurwcuola(fojsslfdoq) = Ten adverse-event reports were received from five patients, including nausea, dizziness/vertigo, bitter taste, sleep disturbance, perceived swelling, arterial hypertension and localized cyanosis of the dorsum of the hand. nthpvchamv (jkiosbfaih )	Positive	11 Jun 2026
EULAR2026	Not Applicable	Rheumatoid Arthritis	254	Filgotinib	vtqrknfnsj(vnlnusxzle) = dvofjtbmdc wfgrwahlhe (tuekmymvao ) View more	Positive	11 Jun 2026
EULAR2026	Phase 4	Rheumatoid Arthritis	1,306	Filgotinib 200 mg (AT-naïve patients)	elvlirsxhl(tyugmwhsvz) = cjktwyajkv inyhfxraqj (wbgnirllgt ) View more	Positive	11 Jun 2026
				Filgotinib 200 mg (patients who had received one prior tumor necrosis factor (TNF) inhibitor)	elvlirsxhl(tyugmwhsvz) = hhmzkcfhlw inyhfxraqj (wbgnirllgt ) View more
DDW2026	Not Applicable	Colitis, Ulcerative	230	Vedolizumab	jhuvyksmbg(ygtuowmqay): P-Value = 0.47 View more	Positive	02 May 2026
				Filgotinib